288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Shanghai 200131
China
86 21 5046 1111
https://www.wuxiapptec.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 41,116
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Ge Li Ph.D. | Co-Founder, Chairman, President & CEO | 5.91M | N/A | 1967 |
Dr. Minzhang Chen Ph.D. | Co-CEO & Executive Director | 1.54M | N/A | 1969 |
Dr. Qing Yang Ph.D. | Co-CEO & Executive Director | 1.07M | N/A | 1969 |
Dr. Edward Hu M.B.A. | Vice Chairman, Global Chief Investment Officer, CEO of WuXi ATU & Head of DDSU | 1.18M | N/A | 1962 |
Ms. Ming Shi | Senior VP & CFO | N/A | N/A | 1974 |
Mr. Zhaohui Zhang | COO of China, Executive VP & Executive Director | 991.51k | N/A | 1969 |
Mr. Yuanzhou Zhang | Joint Company Secretary | N/A | N/A | 1988 |
Mr. Ruijia Tang | IR Director | N/A | N/A | N/A |
Dr. Jingchao Dong Ph.D. | Senior VP & Head of RCS | N/A | N/A | N/A |
Mr. Tao Guo Ph.D. | Senior VP and Head of RCS BD&IPM | N/A | N/A | N/A |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; and drug discovery services to pharmaceutical and biotech customers. In addition, the company offers consulting services for combinatorial chemistry and pharmaceuticals; and develops computer software and databases. Further, it is involved in pharmaceutical research and development; pharmacology, toxicology, and safety evaluation research services; and new drug clinical development and on-site management services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
WuXi AppTec Co., Ltd.’s ISS governance QualityScore as of 1 June 2024 is 3. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 9; Compensation: 3.